![PDF) Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms | published in Journal of Crohn s and Colitis PDF) Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms | published in Journal of Crohn s and Colitis](https://i1.rgstatic.net/publication/350787153_Dose-optimization_for_loss-of-response_to_vedolizumab_-_pharmacokinetics_and_immune_mechanisms/links/609003f9458515d315f36c79/largepreview.png)
PDF) Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms | published in Journal of Crohn s and Colitis
![PDF) Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study | Peter Bampton - Academia.edu PDF) Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study | Peter Bampton - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/69213294/mini_magick20210908-7738-1io5vii.png?1631134388)
PDF) Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study | Peter Bampton - Academia.edu
![PDF) Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts PDF) Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts](https://i1.rgstatic.net/publication/352170183_Effectiveness_and_Safety_of_Adalimumab_Biosimilar_SB5_in_IBD_Outcomes_in_Originator_to_SB5_Switch_Double_Biosimilar_Switch_and_Bio-Naieve_SB5_Observational_Cohorts/links/613515bfc69a4e48797d9ee2/largepreview.png)
PDF) Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts
![A Letter to the Right Honourable William Beckford, Lord-Mayor, and Conservator of the River Thames and Waters of Medway; From Sir Stephen Theodore Janssen, Bart. Chamberlain of London. by Janssen, Stephen Theodore - A Letter to the Right Honourable William Beckford, Lord-Mayor, and Conservator of the River Thames and Waters of Medway; From Sir Stephen Theodore Janssen, Bart. Chamberlain of London. by Janssen, Stephen Theodore -](https://m.media-amazon.com/images/I/51Lobd8wevL._AC_SY580_.jpg)
A Letter to the Right Honourable William Beckford, Lord-Mayor, and Conservator of the River Thames and Waters of Medway; From Sir Stephen Theodore Janssen, Bart. Chamberlain of London. by Janssen, Stephen Theodore -
![PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment](https://i1.rgstatic.net/publication/352704305_Biologics_recommendations_in_the_ECCO_guidelines_on_therapeutics_in_Crohn's_disease_Medical_treatment/links/60d9c15392851ca9449080ce/largepreview.png)
PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment
![Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective](https://www.frontiersin.org/files/Articles/655054/fphar-12-655054-HTML-r1/image_m/fphar-12-655054-g001.jpg)